A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis
1 other identifier
interventional
N/A
1 country
1
Brief Summary
The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2002
CompletedFirst Submitted
Initial submission to the registry
August 1, 2002
CompletedFirst Posted
Study publicly available on registry
August 5, 2002
CompletedJune 24, 2005
January 1, 2004
August 1, 2002
June 23, 2005
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Current diagnosis of community-acquired pneumonia.
- Evidence of systemic inflammatory response to infection.
You may not qualify if:
- Atypical or viral pneumonia based on clinical or epidemiologic suspicion by the investigator.
- Presence of organ failure.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- ICOS Corporationlead
Study Sites (1)
ICOS Corporation
Bothell, Washington, 98021, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
August 1, 2002
First Posted
August 5, 2002
Study Start
May 1, 2002
Last Updated
June 24, 2005
Record last verified: 2004-01